FilingReader Intelligence
Sino Biopharmaceutical acquires LaNova, starts cancer drug trial
July 22, 2025 at 08:50 AM UTC•By FilingReader AI
Sino Biopharmaceutical completed its acquisition of LaNova Medicines, adding RMB1.93bn in net assets. LaNova generated RMB4.22bn revenue and RMB1.69bn net profit in the six months to June 30.
The company also began dosing the first patient with TQB6411, a new cancer drug targeting advanced malignant tumors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:1177•Hong Kong Exchange
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime